Table 2.
Participants (N and %) with serum anti-SARS-CoV-2 (S1) IgG-positive status based on indicated months in the 2019–2021 group, OR (August 2019–March 2021 vs. April 2021–August 2021) = 4.1; 95% CI 1.05–16.4; p = 0.04).
| Months | Participants (N) | Participants with Serum Anti-SARS-CoV-2-S1 IgG-Positive Status (%) |
|---|---|---|
| August–September 2019 | 27 | 3.7 |
| October–December 2019 | 53 | 5.7 |
| January–February 2020 | 32 | 6.3 |
| March–May 2020 | 11 | 27.3 |
| June–July 2020 | 41 | 19.5 |
| August–September 2020 | 30 | 16.7 |
| October–December 2020 | 19 | 15.8 |
| January–February 2021 | 8 | 25.0 |
| March 2021 | 25 | 8.0 |
| April 2021 | 22 | 54.5 |
| May 2021 | 11 | 72.7 |
| June 2021 | 14 | 64.3 |
| July 2021 | 13 | 61.5 |
| August 2021 | 4 | 75 |